cyrilzakka/clinical-trials huggingface dataset:
Blood Pressure Changes During Moderate Intensity Strength Training in Aortic Stent-graft Patients

Patients with an aortic stent graft are recommended to do muscle strengthening exercise as part of their rehabilitation. But, as excess blood pressure pose a risk to the integrity of the stent graft, high intensity muscle strengthening exercise may potentially be detrimental, and hence moderate intensity muscle strengthening is recommended. However, the blood pressure changes during moderate intensity strengthening exercises are unknown, and this study aims to quantify these among patients and compare them to those of healthy volunteers.

Purpose:

The purpose of this study is to investigate the increase in blood pressure during quadriceps muscle strength training in patients with aortic stent graft.

Methods:

Patients with aortic stent graft will be included. The participants are investigated once. During the investigation, the blood pressure increase during a single strength training exercise (leg press) is measured. The strength training exercise is done at 60% of maximal strength (moderate intensity) corresponding to 15 Repitition Maximum (RM) (a load that can be lifted exactly 15 times).


Eligibility Criteria:
Inclusion Criteria patients:

* Adults (+18y) with aortic stent graft following aortic dissection or aneurism
* Minimum 8 weeks post surgery
* Strengthening exercise approved by treating cardiologist
* Able to perform the exercise

Exclusion Criteria patients:

* Lack of ability to read, speak or understand instructions in Danish or English
* Other unspecified heart disease

Inclusion Criteria healthy volunteers:

* Adults (+18y)
* In good health (self report)

Exclusion Criteria healthy volunteers:

• Lack of ability to read, speak or understand instructions in Danish or English
INR Comparison Testing in Cardiac Surgery

The investigator is testing blood samples to compare the results of two different techniques. Since blood loss and the need for blood transfusions continue to be major problems after heart surgery and other types of surgery, the blood clotting levels are constantly checked during heart surgery as part of clinical care.The purpose of this study is to compare the INR levels in blood before and after the heart bypass during surgery.


Eligibility Criteria:
Inclusion Criteria:

* Patients greater than or equal to 18 years of age.
* Patients undergoing elective surgery.
* Patients undergoing cardiac surgery.
* Patients to undergo general anesthesia with endotracheal intubation.
* Patients with well-controlled health disorders.

Exclusion Criteria:

* Patients currently on Coumadin or other anticoagulants; including, direct thrombin inhibitors and direct Xa inhibitors.
* Patients who are under 18 years of age or pregnant.
* Patients undergoing emergency surgery.
* Patients with known coagulation disorders.
* Patients who are unable to provide informed consent in the form of a signature
Prevalence of Bacteria Following Endodontic Treatment

Sampling of accessed root canals with endodontic paper points during treatment and immediately pre-obturation of endodontic root canals was carried out.

Following ethical approval (REC ref: 05/Q0705/051), informed consent was obtained from patients undergoing root canal treatment.The teeth included in the study had been referred to a specialist centre for the treatment of endodontic infection. They all responded negatively to vitality tests and presented pre-operative apical radiolucencies. The source population were referred by their general dental practitioner into specialist endodontic clinics of Guy's Hospital, King's College London Dental Institute.Treatments on the teeth were carried out by a total of 19 postgraduate endodontic students.

Eligibility Criteria:
Inclusion Criteria:

* Patients with single or multi-rooted teeth undergoing root canal treatment.

Exclusion Criteria:

* For certain aspects of the study secondary treatments and vital teeth are excluded.
An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter

Magnetic Esophageal Sphincter implant is intended to reinforce Esophageal Sphincter function in the treatment of Gastroesophageal Reflux Disease (GERD)

The purpose of this feasibility study is to collect preliminary performance and safety information and develop procedural optimization for the Torax Medical Inc. Magnetic Esophageal Sphincter device (MES) in reinforcement of Esophageal Sphincter function to treat Gastroesophageal Reflux Disease (GERD). The information from this study will be used to support the design and conduct of an expanded clinical trial.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years, \< 85 years, life expectancy \> 3yrs.
* Documented history of GERD symptoms such as heartburn and/or regurgitation.
* On daily PPI treatment for at least 3-months.
* Responsive to PPI treatment.
* GERD symptoms, in absence of PPI therapy (minimum 10 days).
* Ambulatory Esophageal pH \< 4 for ≥ 5% time or pH \< 4 for ≥ 3% time in supine position.
* Patient is a surgical candidate.
* Patient is willing and able to cooperate with follow-up examinations.
* Patient has been informed of the study procedures and the treatment and has signed an informed consent form and provided authorization to use and disclose information for research purposes (HIPAA).

Exclusion Criteria:

* The procedure is an emergency procedure.
* Patient is currently being treated with another investigational drug or investigational device.
* Patient has had prior gastric or esophageal surgery.
* Patient has had any previous endoscopic intervention for GERD
* Patient has suspected or confirmed esophageal or gastric cancer.
* Patient has any size paraesophageal hiatal hernia or sliding hiatal hernia ≥3cm. (Investigator to identify and record type of hiatal hernia at the time of assessment (i.e. para-esophageal, sliding)).
* Patient's esophageal motility is less than 35 mmHg peristaltic amplitude on wet swallows or \> 30% failed (non-propulsive) peristaltic sequences.
* Patient has esophagitis - Grade B, C, D (LA Classification).
* Patient has Barretts Esophagus.
* Patient has BMI \> 35.
* Patient has symptoms of dysphagia or indications of dysphagia from barium esophagram.
* Patient has Scleroderma and/or Achalasia.
* Patient has an esophageal stricture or gross esophageal anatomic abnormalities (obstructive lesions, etc.).
* Patient has an electrical implant or metallic, abdominal implant(s).
* Patient cannot understand trial requirements or is unable to comply with follow-up schedule.
* Patient is pregnant or nursing, or plans to become pregnant.
* Patient has a psychiatric disorder.
Minimally-invasive Surgery Versus Craniotomy in Patients With Supratentorial Hypertensive Intracerebral Hemorrhage

The effectiveness of craniotomy in the treatment of intracerebral hemorrhage remains controversial. Two main types of minimally invasive surgery, endoscopic evacuation and stereotactic aspiration, have been attempted for hematoma removal and show some advantages. However, prospective and controlled studies are still lacking. This is a multi-center randomized controlled trial designed to determine whether minimally invasive hematoma evacuation with endoscopic or stereotactic aspiration will improve the outcome in patients with hypertensive intracerebral hemorrhage compared with small-boneflap craniotomy. Patients will be randomly assigned to endoscopy group, stereotactic aspiration group or small-boneflap craniotomy group in a 1:1:1 ratio.

Hypertensive intracerebral hemorrhage (HICH) is the most common hemorrhagic stroke. The morbidity and mortality exceed 60% and only 12% patients could live independently. The choice of surgical or conservative treatment for patients with HICH is controversial.

Some minimally invasive neurosurgeries have been applied to hematoma evacuation and may improve prognosis to some extent. In endoscopic evacuation, a small burr hole is created and hematoma is removed through suction and irrigation under neuroendoscope. Endoscopic surgical evacuation promise to maximize hematoma evacuation while minimizing damage to normal tissue. Stereotactic aspiration uses image guidance to place a catheter into the main body of the hematoma and aspirate blood. It is estimated that 720 patients (240 patients in each treatment group) would provide 90% power and a type I error probability of .05 to detect an effect size of 13% with a 10% dropout rate taken into consideration. Patients will receive endoscopic evacuation, stereotactic aspiration or craniotomy according to the results of randomization. Patients will be followed up at 7 days, 30 days and 6 months.

Outcomes of different groups of patients will be collected and compared. The study is designed to find a best surgical method for hypertensive intracerebral hemorrhage.

Eligibility Criteria:
Inclusion Criteria:

* Supratentorial hypertensive intracerebral hemorrhage on CT scan with the hematoma volume ≥25mL
* Adult patients with GCS score ≥5
* Admitted within 24h of ictus

Exclusion Criteria:

* Intracerebral hemorrhage caused by tumor, coagulopathy, aneurysm, or arteriovenous malformation
* Concurrent head injury or history of head injury
* Multiple intracerebral hemorrhage
* Known advanced demential or disability before
* With indications of terminal brain hernia
* Severe concomitant diseases that affect life expectancy
* Patients having taken anti-platelet or anticoagulant drugs for a long time
* With severe intraventricular hemorrhage
* Pregnant women
Can the Hypertrophy of Contralateral Testis Predict the Absence of the Non-palpable Testis in the Boys Aged From 6months to 18months of Age ?

The aim of this study is to verify whether the hypertrophy of contralateral testis may predict the absence of the non-palpable testis in the boys younger than 24months of age. According to the previous studies of other countries, the large size of the contralateral testis of the nonpalpable testis has positive correlation woth the weak viability of the affected testis. We are going to evaluate this hypothesis with prospective study. 3 groups are going to be enrolled into this study ; non-palpable testis group(Group1), palpable but not normally descended testis group(group2) and control group(group3). The size of testis will be measured with Ultrasound and the length, width and the height will be measured before surgery at outpatient department. For the group 1 \& 2, the viability of the affected testis will be evaluated and compared after surgery. In addition the comparison with normal control group is also going th be conducted.


Eligibility Criteria:
Inclusion Criteria:

1. neonates or Infants who visited the out-patient clinic with nonpalpable or undescended testis.(group 1, 2) aged from 6months to 18months
2. neonates or Infants aged from 6months to 18months with normal testis (volunteers, Group3)

Exclusion Criteria:

1. previous history of hormonal therapy.
2. chromosomal abnormality
3. previous history of abdomen or inguinal area surgery
4. children diagnosed with epididymitis or orchitis
5. twin baby
6. infants with premature (\<37 weeks) birth history
Comparison of Remimazolam With Flumazenil vs. Propofol During RFCA for Atrial Fibrillation

This prospective randomized trial aims to compare recovery time from discontinuation of remimazolam followed by flumazenil administration vs. propofol total intravenous anesthesia as the main general anesthetics during radiofrequency catheter ablation treatment of atrial fibrillation.

Adult patients with atrial fibrillation undergoing radiofrequency catheter ablation under general anesthesia are randomized to receive either remimazolam with flumazenil or propofol total intravenous anesthesia as the main anesthetics. After completion of radiofrequency ablation, each anesthetic is discontinued. The primary outcome of the study is comparison of the time to the first eye opening responding to doctor's command from the discontinuation of each drug between the groups. Secondary outcomes includes the time to removal of supraglottic laryngeal mask airway device from discontinuation of each drug, incidence of three consecutive hypotension (systolic blood pressure under 80 mmHg) recordings at 2.5 min-intervals, and intraprocedural vasoactive-inotropic score.

Eligibility Criteria:
Inclusion Criteria:

* Adult patient, age 20-75 years, scheduled for radiofrequency catheter ablation of atrial fibrillation under general anesthesia

Exclusion Criteria:

* Patients who are not alert before procedure
* Hemodynamicaly unstable patients before procedure
* Patients with history of adverse reaction of allergic reaction to study drugs
* Patients who are anticipated to be unable to remove supraglottic airway or endotracheal tube due to severe dyspnea or need for mechanical ventilatory support
* Use of sedatives (anxiolytics, psychoactive medication, antidepressants, hypnotics) within 24 h
* Known galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
* Severe hepatic or renal dysfunction
* Alcohol or drug dependence
* Organic brain disorder
* Spinal or cerebellar ataxia
* Acute narrow-angle glaucoma
* Patients with shock or coma
* Pregnant or lactating women
* Patients with hypersensitive to beans or peanut
* Patients who refuse to participate
A Case-control Study on Risk Factors, Timing, and PCR Use, for Pneumocystis Pneumonia (PcP) After Allogeneic HSCT

The fungus Pneumocystis jirovecii is responsible for pneumocystosis (PcP), a life threatening pneumonia in patients undergoing HSCT. The spontaneous attack rate of 16% within the first 6 months following allogeneic HSCT reported in the 1980's has considerably decreased with prophylaxis. However, PcP still remains a concern in the transplant ward with an incidence rate up to 2.5% in allo- and 1.4% in autologous HSCT but up to 7.2% on low dose of Dapsone. The mortality of PcP is especially high in HSCT recipients. One of the main factors of PcP after HSCT seems to be either the lack of TMP-SMX prophylaxis (all the other prophylactic drugs being inferior to TMP-SMX), or poor compliance to prophylaxis. Due to the rarity of the disease after HSCT, it is impossible to study it in monocenter studies, except on very long periods of time which may not reflect current practice. Several questions deserve investigations in a multicenter study, about timing, risk factors, and outcome.

Moreover, some European laboratories involved in the diagnosis of PcP have already given up to classical diagnostic methods and switched to qPCR. This implies that lower fungal burden can be detected and the clinical pertinence of such a diagnostic strategy deserves to be assessed.

Due to the lack of standardization, qPCR on sputum only will not be taken in account for the diagnosis of PcP. Knowing this is a non-interventional study, no additional visits or laboratory tests will be performed for the study. Only the available data will be collected.

Eligibility Criteria:
Inclusion Criteria PCP cases:

* Allogeneic HSCT within the previous 24 months
* New case (first onset) of PcP documented in a BAL fluid, whatever the positive diagnostic test (cytology or IF or PCR) and whatever the presentation and treatment
* Any age
* Pre or post-transplant signed informed consent to enter the data in the EBMT registry

Exclusion Criteria PCP cases:

* Autologous HSCT
* Allogeneic HSCT recipient transplanted more than 24 months at time of the onset of PcP
* Second episode of PcP since allogeneic HSCT (patients who had experienced PcP before the allogeneic HSCT are not excluded).
Effect of Rosuvastatin in Intracerebral Hemorrhage

The purpose of this study is to determine whether rosuvastatin is effective in the management of acute phase of intracerebral hemorrhage and if it impact outcome by NIHSS.

The intracerebral hemorrhage (ICH) is a frequent problem of health, with high morbid-mortality. In addition it originates expensive expenses in health care systems.

ICH produces damage by mass effect, then by biochemical ways which are activated and they carry to secondary damage. Many studies have been conducted for explaining secondary injury, now we know there are ischemic changes related maybe with changes in cerebral flow and metabolism, in addition to activate inflammatory ways. Many drugs and measures has been ineffective for getting best outcome, without success.

Statins or inhibitors of HMG CoA reductase are drugs used in dyslipidemia, frequently for reduction in LDL. Experimental and clinical studies in stroke and ICH have shown improvement in outcome. The toxicity related to statin is myopathy and hepatopathy, both with low incidence without fatal cases. Rosuvastatin has been postulated be the most powerful with longest life and toxicity similar to another statins.

We have designed this study to demonstrate if the administration of rosuvastatin in the first 24 hours and by 14 days has improvement in outcome.

Eligibility Criteria:
Inclusion Criteria:

* Men or Women \>16 and \< 80 years with ICH and hospital attention in less 24 hours
* Confirmation by CT scan
* Acceptance by family

Exclusion Criteria:

* History of stroke
* History of neurological disease, head injury o psychiatric disorder with disability
* Glasgow less than 9
* Administration 24 hours before: fibrates, niacin, ciclosporin, azoles, macrolides, inhibitors of protease, nefazodone, verapamil, diltiazem, amiodarone.
* Use before hospital of: mannitol, barbiturates, corticosteroids, calcium antagonists
* Any lesion which needs surgery
* Allergy to drug used
* cerebral death
* Hepatic disease (Child B y C) or myopathy (or) history
* Management in other Hospital
* Pregnancy
* ICH major than 60 ml.
* hypothyroidism
Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

The aim of this trial is to develop an effective and well-tolerated regimen for treatment of r/r cHL by introducing the anti-PD-1 antibody pembrolizumab and adding it to well-established chemotherapy regimens (ICE, DHAP). Synergistic effects of conventional agents with checkpoint inhibition may facilitate a highly effective therapy with limited toxicity, which might eventually substitute the very toxic high-dose chemotherapy (HDCT).


Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed first relapse of cHL or primary refractory cHL

Exclusion Criteria:

* Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma
Performance Assessment of a Remote Patient Monitoring Device

This study will evaluate the performance of the Zephyr BioPatch in measuring heart rate, respiration rate, posture, and activity level compared to reference devices in healthy adult subjects during a variety of situations including hospital room movements, talking, and a short bout of exercise.


Eligibility Criteria:
Inclusion Criteria:

1. Signed and dated informed consent by subject or legally authorized representative (LAR)
2. Male or female of any race
3. 18-50 years of age, inclusive
4. Willingness to have study devices attached during study participation
5. Willingness to participate in all aspects of the study
6. Ability to walk without human assistance or walking aides (e.g. cane or walker), in the opinion of the investigator

Exclusion Criteria:

1. Subject is unable to provide informed consent
2. Under 18 years of age or over 50 years of age
3. Implanted pacemaker or defibrillator
4. Diagnosis of atrial fibrillation as reported by the subject
5. Current hospital admission
6. History of hospital admission or a surgical procedure in the 60 days prior to study enrollment
7. Any contraindications to protocol specific repositioning techniques (e.g. turning on right side or left side or lying in supine position)
8. Female subject is pregnant and/or lactating as reported by the subject
9. Subject is considered as being morbidly obese (defined as BMI \>39.5)
10. Subject is on any medications, in the opinion of the investigator, that would impair heart response during the short bout of exercise
11. A serious concurrent medical or other condition, in the opinion of the investigator, that would impair protocol compliance or safety of the subject
An Intervention Study to Reduce Drug-related Problems and Readmissions Among Old People With Dementia

The aim of this randomized controlled study is to investigate if medication reviews performed by a clinical pharmacist as part of a ward team can reduce drug related problems and reduce readmissions to hospital among elderly patients (≥65 years) with dementia and cognitive failure.

Four hundred and sixty patients will be recruited and randomized to control (usual care) and intervention group (enhanced service in which a pharmacist is part of the health care team).

Six months after the last patient of the 460 has been discharged the study will be closed. Data about the number of readmissions and visits to the emergency room will be collected during the six-month follow-up and also, the costs associated with each visit or admission. Time until institutionalization will be compared between intervention group and control group.


Eligibility Criteria:
Inclusion Criteria:

* Patients with dementia or cognitive impairment
* Patients ≥ 65 years

Exclusion Criteria:

* Patients previously admitted to the study wards during the study period
Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study

The purpose of this study is to quantify and publish participants' relative preferences for outcomes of chemotherapy and novel oral hormonal agents when added to androgen deprivation therapy (ADT) for participants with locally-advanced and metastatic hormone-sensitive prostate cancer (mHSPC). This study will also quantify the importance of administration factors related to convenience relative to treatment outcomes.

The study will develop and administer a discrete-choice experiment (DCE) to quantify tradeoff preferences of participants with mHSPC and locally-advanced prostate cancer in various countries. Data/surveys are being collected in: United States, Canada, UK, France, Spain, Japan, China and South Korea.

Eligibility Criteria:
Inclusion Criteria:

For interviews (attribute prioritization and pretest interviews)

* Diagnosis of mHSPC with or without previous experience with ADT
* Able to read and understand the survey language
* Able to provide informed consent For online survey
* Diagnosis of mHSPC or locally-advanced prostate cancer with or without previous experience with ADT
* Able to read and understand the survey language
* Able to provide informed consent

Exclusion Criteria:

Not applicable